Unknown

Dataset Information

0

When is dual bronchodilation indicated in COPD?


ABSTRACT: Inhaled bronchodilator medications are central to the management of COPD and are frequently given on a regular basis to prevent or reduce symptoms. While short-acting bronchodilators are a treatment option for people with relatively few COPD symptoms and at low risk of exacerbations, for the majority of patients with significant breathlessness at the time of diagnosis, long-acting bronchodilators may be required. Dual bronchodilation with a long-acting β2-agonist and long-acting muscarinic antagonist may be more effective treatment for some of these patients, with the aim of improving symptoms. This combination may also reduce the rate of exacerbations compared with a bronchodilator-inhaled corticosteroid combination in those with a history of exacerbations. However, there is currently a lack of guidance on clinical indicators suggesting which patients should step up from mono- to dual bronchodilation. In this article, we discuss a number of clinical indicators that could prompt a patient and physician to consider treatment escalation, while being mindful of the need to avoid unnecessary polypharmacy. These indicators include insufficient symptomatic response, a sustained increased requirement for rescue medication, suboptimal 24-hour symptom control, deteriorating symptoms, the occurrence of exacerbations, COPD-related hospitalization, and reductions in lung function. Future research is required to provide a better understanding of the optimal timing and benefits of treatment escalation and to identify the appropriate tools to inform this decision.

SUBMITTER: Thomas M 

PROVIDER: S-EPMC5546730 | biostudies-other | 2017

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC5221557 | biostudies-literature
| PRJEB20508 | ENA
| S-EPMC6437647 | biostudies-literature
| S-EPMC7011474 | biostudies-literature
| S-EPMC6214575 | biostudies-literature
| PRJEB29062 | ENA
| PRJEB13652 | ENA
| PRJEB8320 | ENA
| S-EPMC5723113 | biostudies-literature
| S-EPMC5147776 | biostudies-literature